Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
Abstract Background Triple-negative breast cancer (TNBC), the subtype of breast cancer with the highest mortality rate, shows clinical characteristics of high heterogeneity, aggressiveness, easy recurrence, and poor prognosis, which is due to lack of expression of estrogen, progesterone receptor and...
Main Authors: | Canling Lin, Jiajun Cui, Zhen Peng, Kai Qian, Runwen Wu, Yimin Cheng, Weihua Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | European Journal of Medical Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40001-022-00839-0 |
Similar Items
-
Platinum chemotherapy for early triple-negative breast cancer
by: Sofia RE. Mason, et al.
Published: (2024-06-01) -
Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
by: Junjie Li, et al.
Published: (2022-05-01) -
Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial
by: Safa Najafi, et al.
Published: (2017-03-01) -
Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation
by: Suzanne van der Gaag, et al.
Published: (2024-04-01) -
Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
by: Kuojun Ren, et al.
Published: (2024-10-01)